<DOC>
	<DOC>NCT02379741</DOC>
	<brief_summary>The purpose of this study is to determine whether ADC-1013 (an agonistic human monoclonal IgG1 anti-CD40 antibody) is safe and tolerable when administered intratumorally (as repeated injections directly into the tumor tissue) or intravenously (as repeated doses directly into a vein) in patients with advanced solid tumors.</brief_summary>
	<brief_title>ADC-1013 First-in-Human Study</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Major Diagnosis of advanced solid tumor disease Performance status of 01 on the ECOG scale Life expectancy of at least 3 months Major Organ transplant recipient Autoimmune disorder Other malignancy (except localized prostate cancer, adequately treated basal skin cancer or carcinoma insitu of the cervix)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Antibodies</keyword>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>Antineoplastic agent</keyword>
	<keyword>Physiological effects of drugs</keyword>
	<keyword>Therapeutic uses</keyword>
	<keyword>Clinical Trial, Phase I</keyword>
	<keyword>Immunotherapy, Active</keyword>
	<keyword>CD40 Antigen</keyword>
	<keyword>Immunologic Factors</keyword>
	<keyword>Injections, Intralesional</keyword>
</DOC>